|1.||Luo, Y: 2 articles (08/2007 - 03/2006)|
|2.||Leverson, J D: 2 articles (08/2007 - 03/2006)|
|3.||Woods, K W: 2 articles (08/2007 - 03/2006)|
|4.||Giranda, V L: 2 articles (08/2007 - 03/2006)|
|5.||Loegering, David A: 1 article (05/2014)|
|6.||Flatten, Karen S: 1 article (05/2014)|
|7.||Kaufmann, Scott H: 1 article (05/2014)|
|8.||Schneider, Paula A: 1 article (05/2014)|
|9.||Erlichman, Charles: 1 article (05/2014)|
|10.||Peterson, Kevin L: 1 article (05/2014)|
|1.||Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
09/01/2008 - "Because activated AKT is seen in a large percentage of patients with T-ALL, A443654, either alone or in combination with existing drugs, may be a useful therapy for primary and drug-resistant T-ALL."
09/01/2008 - "Here, we report that the novel AKT inhibitor (2S)-1-(1H-indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) leads to rapid cell death of T-ALL lines and patient samples. "
09/01/2008 - "The efficacy of A443654 was confirmed using blasts from six patients with T-ALL, all of whom displayed low levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and constitutive phosphorylation of Akt on Ser473. "
|2.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
10/01/2010 - "Rapamycin and A-443654 in combination induced apoptosis at earlier times and at lower A-443654 concentrations in MCF10CA1a tumor cells than in the benign MCF10A cells. "
08/16/2007 - "We report that A-443654, a potent small-molecule inhibitor of Akt serine/threonine kinases, induces Akt Ser-473 phosphorylation in all human cancer cell lines tested, including PTEN- and TSC2-deficient lines. "
03/02/2006 - "In order to identify Akt-cooperating kinases, we screened a library of kinase-directed small interfering RNAs (siRNAs) for enhanced cancer cell killing in the presence of Akt inhibitor A-443654. "
10/01/2010 - "Rapamycin and A-443654 increased p53 and p15(INK4B) protein levels, decreased anti-apoptotic Bcl-2 levels, and increased Bad levels in the MCF10CA1a tumor cells by approximately 5-fold. "
05/01/2007 - "Importantly, whereas combining A-443654 with rapamycin had variable effect on cell proliferation, the combination essentially blocked hypoxia-driven increases in VEGF in all cell lines examined, suggesting that dual blockade at different levels in the phosphatidylinositol 3'-kinase-initiated signaling pathway may be a reasonable strategy for preventing VEGF production in cancer cells derived from pediatric solid tumors. "
|4.||Glioblastoma (Glioblastoma Multiforme)
02/01/2009 - "A-443654 was further tested in a rat intracranial model of glioblastoma multiforme. "
05/01/2011 - "CsA, comparably to pharmacological inhibitors of PI3K/Akt signaling (LY294002, A443654), reduced motility of glioblastoma cells, diminished MMP-2 gelatinolytic activity and MMP-2 and MT1-MMP expression. "
|5.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|3.||Matrix Metalloproteinase 14 (MT1-MMP)
|4.||Cyclin-Dependent Kinase Inhibitor p15
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Small Interfering RNA (siRNA)
|7.||Protein-Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)